Adalimumab 80 mg weekly dose escalation for hidradenitis suppurativa: a multicentre retrospective cohort study incorporating therapeutic drug monitoring

Clinical and Experimental Dermatology 2026 Open access

Read full text
Authors: Hannah Wainman, Ser Ling Chua, Donal O’Kane, Sarah Helen Mehrtens, John Robert Ingram
DOI: 10.1093/ced/llag044
Cited by: 0

Abstract

We conducted a retrospective cohort study across four UK centres to establish whether therapeutic drug monitoring and dose escalation of adalimumab up to 80 mg weekly improved patient outcomes. This study represents one of the largest cohorts examining therapeutic drug monitoring and high-dose adalimumab in patients with hidradenitis suppurativa. Unlike previous studies, we did not observe significant mean improvements across standardized outcome measures, despite over 50% of patients being assessed by their clinicians as showing overall improvement.

Fields of Study & Subjects

Hidradenitis Suppurativa and Treatments Autoimmune and Inflammatory Disorders Osteomyelitis and Bone Disorders Research

Publication details

Journal / source
Clinical and Experimental Dermatology
Volume
51
Issue
6
Pages
1104–1106
Publication date
24 January 2026
Language
EN